CGEN
Compugen Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.49
+1.22%0
Insider buys (3m)
1
Insider sells (3m)
-$4.7K
Net value (3m)
+18.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 30, 2026 | Levine Zurit · officer: SVP, Business Development | A-Award | 18,000 | $0.00 |
| Jul 30, 2026 | Mahler Michelle · officer: Chief Medical Officer | A-Award | 18,000 | $2.26 |
| Jul 30, 2026 | Mahler Michelle · officer: Chief Medical Officer | A-Award | 13,500 | $0.00 |
| Jul 30, 2026 | ZWEIFACH SANFORD S · director | A-Award | 10,000 | $2.26 |
| Jul 30, 2026 | ZWEIFACH SANFORD S · director | A-Award | 7,500 | $0.00 |
| Jul 30, 2026 | Halevy Gilead · director | A-Award | 10,000 | $2.26 |
| Jul 30, 2026 | Halevy Gilead · director | A-Award | 7,500 | $0.00 |
| Jul 30, 2026 | Hukkelhoven Mathias · director | A-Award | 10,000 | $2.26 |
| Jul 30, 2026 | Hukkelhoven Mathias · director | A-Award | 7,500 | $0.00 |
| Jul 30, 2026 | Livnat Savitzky Kinneret · director | A-Award | 10,000 | $2.26 |
| Jul 30, 2026 | Livnat Savitzky Kinneret · director | A-Award | 7,500 | $0.00 |
| Jul 30, 2026 | Kredo Russo Sharon · officer: SVP, Research & Discovery | A-Award | 24,000 | $2.26 |
| Jul 30, 2026 | Kredo Russo Sharon · officer: SVP, Research & Discovery | A-Award | 18,000 | $0.00 |
| Jul 30, 2026 | Ferre Pierre · officer: Chief Operating Officer | A-Award | 70,000 | $4.00 |
| Jul 30, 2026 | Perry Eran · director | A-Award | 10,000 | $2.26 |
| Jul 30, 2026 | Perry Eran · director | A-Award | 7,500 | $0.00 |
| Jul 30, 2026 | Cohen-Dayag Anat · director | A-Award | 100,000 | $2.26 |
| Jul 30, 2026 | Ophir Eran · director, officer: President and CEO | A-Award | 200,000 | $2.26 |
| Jul 30, 2026 | Silberman David · officer: Chief Financial Officer | A-Award | 26,000 | $2.26 |
| Jul 30, 2026 | Silberman David · officer: Chief Financial Officer | A-Award | 19,500 | $0.00 |
| Jul 30, 2026 | Levine Zurit · officer: SVP, Business Development | A-Award | 24,000 | $2.26 |
| Jul 13, 2026 | Levine Zurit · officer: SVP, Business Development | M-Exempt | 1,875 | $0.83 |
| Jul 13, 2026 | Levine Zurit · officer: SVP, Business Development | Sale | 1,875 | $2.50 |
| Apr 27, 2026 | Levine Zurit · officer: SVP, Business Development | M-Exempt | 2,000 | $1.15 |
| Apr 27, 2026 | Ophir Eran · director, officer: President and CEO | Sale | 5,000 | $3.20 |
| Apr 27, 2026 | Ophir Eran · director, officer: President and CEO | M-Exempt | 5,000 | $0.83 |
| Apr 27, 2026 | Levine Zurit · officer: SVP, Business Development | Sale | 2,000 | $3.20 |
| Apr 15, 2026 | Ophir Eran · director, officer: President and CEO | Sale | 5,000 | $2.90 |
| Apr 15, 2026 | Levine Zurit · officer: SVP, Business Development | Sale | 2,000 | $2.80 |
| Apr 15, 2026 | Levine Zurit · officer: SVP, Business Development | M-Exempt | 2,000 | $1.15 |
Institutional positioning
13F filings over the trailing two quarters
New 28Increased 33Reduced 38Sold out 12
| Filer | Action | Shares | Filed |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | Reduced | 3,315,845 | May 14, 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | Reduced | 3,184,257 | Aug 13, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 1,877,500 | Aug 13, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 1,632,988 | May 14, 2026 |
| MORGAN STANLEY | Reduced | 1,053,229 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 1,051,986 | Aug 13, 2026 |
| ARK INVESTMENT MANAGEMENT LLC | New Position | 1,049,873 | May 12, 2026 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | Unchanged | 1,020,000 | Aug 14, 2026 |
| MACQUARIE MANAGEMENT HOLDINGS, INC. | Unchanged | 1,020,000 | May 15, 2026 |
| TAYLOR FRIGON CAPITAL MANAGEMENT LLC | Reduced | 848,043 | Apr 29, 2026 |
| Taylor Frigon Capital Management LLC | Reduced | 842,181 | Jul 23, 2026 |
| ARK Investment Management LLC | Reduced | 786,536 | Aug 14, 2026 |
| NORTHERN TRUST CORP | Reduced | 650,868 | May 14, 2026 |
| Altshuler Shaham Ltd | Increased | 521,625 | Aug 12, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 521,587 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 30, 2026